Here are 1-3 brief analogies for Pacira BioSciences (PCRX):

• Like Amgen or Gilead Sciences for non-opioid pain solutions.
• Like Medtronic for non-opioid pain management technology.
• Like Moderna for non-opioid pain therapies.

```html

• EXPAREL: A bupivacaine liposome injectable suspension for non-opioid pain management.
• ZILRETTA: A triamcinolone acetonide extended-release injectable suspension for pain management.
• iovera system: A non-opioid handheld cryoanalgesia device that produces controlled doses of cold temperature to targeted nerves.
• Proprietary multivesicular liposome: A drug delivery technology that encapsulates drugs without altering their molecular structure.

```

Pacira BioSciences (PCRX) primarily sells its products through major pharmaceutical wholesalers. These wholesalers then distribute Pacira's non-opioid pain management and regenerative health solutions to hospitals, ambulatory surgical centers, and physician practices across the United States.

Based on the company's public filings, its major customers, representing a significant portion of its product net revenue, are:

• AmerisourceBergen Corporation (Symbol: ABC)
• Cardinal Health, Inc. (Symbol: CAH)
• McKesson Corporation (Symbol: MCK)

null

Frank D. Lee Chief Executive Officer & Director Mr. Lee joined Pacira BioSciences as Chief Executive Officer and a member of the Board of Directors in January 2024. He is an accomplished biopharmaceutical leader with thirty years of global experience. Prior to Pacira, he served as Chief Executive Officer and a director of the publicly traded Forma Therapeutics from March 2019 until its acquisition by Novo Nordisk in October 2022. During his tenure, he transformed Forma Therapeutics from an early-stage drug discovery company into one focused on clinical development. Before Forma, he spent 13 years at Genentech, a member of the Roche Group, in various leadership roles, including Senior Vice President, Global Product Strategy and Therapeutic Area Head for Immunology, Ophthalmology and Infectious Diseases, overseeing global product sales of $11 billion. Earlier in his career, he spent approximately 13 years across Novartis, Janssen, and Eli Lilly in engineering, manufacturing, sales/marketing, and business development. Mr. Lee currently serves as a Director of Bausch Health Companies, Inc. and as an Advisor to Lightstone Ventures. He also served as executive chairman of the board of privately held Therini Bio, Inc. and chairman of the board of privately held Catamaran Bio, Inc., and a member of the board of Bolt Biotherapeutics, Inc. Shawn Cross Chief Financial Officer Mr. Cross was appointed Chief Financial Officer of Pacira BioSciences in October 2024. He brings over 25 years of experience in the biopharmaceutical sector, including as a biotechnology executive, board member, and investment banker. Before joining Pacira, he was a member of the leadership team at Applied Molecular Transport Inc. (AMT), where he served as Chief Financial Officer from March 2020 to May 2022, President and Chief Operating Officer from May 2022 to March 2023, and Chief Executive Officer and a director from March 2023 through the closing of its merger with Cyclo Therapeutics, Inc. in December 2023. He led AMT through its initial public offering. Prior to AMT, Mr. Cross was an investment banker for more than 20 years, focusing on the biopharmaceutical industry, with senior roles at JMP Securities, Deutsche Bank Securities, Wells Fargo Securities, and Thomas Weisel Partners. He began his investment banking career at Alex. Brown & Sons. Mr. Cross currently serves on the board of directors of Cyclo Therapeutics. Brendan Teehan Chief Commercial Officer Mr. Teehan was named Chief Commercial Officer of Pacira BioSciences in January 2025. He is an accomplished biopharmaceutical executive with a 30-year track record of successfully building and leading commercial teams. Prior to joining Pacira, he held various commercial leadership positions at Acadia Pharmaceuticals, Inc., most recently as Chief Operating Officer and Head of Commercial. He also served in commercial leadership roles at Tesaro, Inc., Raintree Oncology Services, Amgen, Inc., and Johnson & Johnson. Mr. Teehan has extensive expertise in both privately and publicly held companies across multiple large and rare disease therapeutic categories and development stages. Krys Corbett Chief Business Officer Ms. Corbett was named Chief Business Officer of Pacira BioSciences in January 2025. She brings more than 25 years of industry experience across business development, strategic transactions, alliance management, and product portfolio management. Before joining Pacira, she led portfolio and product strategy for clinical and preclinical-stage programs at Lyell Immunopharma. She also served as Head of Business Development, General Counsel, and Corporate Secretary for Oric Pharmaceuticals. Earlier in her career, Ms. Corbett held alliance and asset management leadership roles at Roche and Genentech. She began her career at the law firm Wilson Sonsini Goodrich and Rosati. Kristen Williams, Esq. Chief Administrative Officer & Secretary Ms. Williams serves as Chief Administrative Officer & Secretary at Pacira BioSciences. She holds a Bachelor of Science Degree in Business Administration from Bucknell University and a J.D. Degree from the University of Denver, College of Law.

Pacira BioSciences (PCRX) faces several key risks to its business, primarily stemming from its reliance on core products, the ongoing threat of generic competition, and intense market dynamics.

1. High Dependence on Key Products: Pacira BioSciences exhibits a significant dependence on a limited number of products, with EXPAREL and ZILRETTA accounting for 95% of its total revenue in 2024. EXPAREL alone contributed 78% of the company's total revenue in the same year. This concentration makes the company particularly vulnerable to market shifts, regulatory challenges, or competitive pressures impacting these products.

2. Generic Competition and Patent Erosion for EXPAREL: Despite comprehensive patent strategies and recent litigation settlements, the threat of generic competition for its flagship product, EXPAREL, remains a key risk. While some EXPAREL patents extend into the 2040s, a settlement in April 2025 permits volume-limited generic bupivacaine liposome injectable suspension to enter the U.S. market starting in early 2030, with unlimited generic production allowed from 2039. Additionally, a 2024 district court ruling invalidated one of Pacira's patents, potentially opening the door for generic entry, though the manufacturing complexity of EXPAREL’s proprietary multivesicular liposome (pMVL) technology is noted as a significant barrier.

3. Intense Competition and Market Adoption Challenges: The pain management market is highly competitive and dynamic, posing a continuous challenge for Pacira BioSciences. The company faces direct competition from other long-acting anesthetics, such as Heron Therapeutics’ ZYNRELEF, and larger pharmaceutical companies investing in non-opioid pain relief solutions. Moreover, products like ZILRETTA have experienced challenges with market traction and sales force transitions, and the iovera system competes in a field with numerous emerging players. Changes in healthcare policies, insurance coverage, and reimbursement rates also present regulatory and market risks that can impact the profitability and adoption of Pacira's products.

null

Pacira BioSciences, Inc. (symbol: PCRX) operates in the non-opioid pain management and regenerative health solutions markets with its key products EXPAREL, ZILRETTA, and the iovera system.

Here are the addressable market sizes for their main products:

• EXPAREL (bupivacaine liposome injectable suspension): The global EXPAREL market size was valued at approximately $1.2 billion in 2023 and is forecasted to reach $3.1 billion by 2032. North America accounted for approximately 45% of the global market in 2023.
• ZILRETTA (triamcinolone acetonide extended-release injectable suspension): The broader global intra-articular corticosteroid market, which includes ZILRETTA, was valued at approximately $1.6 billion globally in 2022. More specifically for its indication, the U.S. knee osteoarthritis (OA) injectable treatments market size was $1.02 billion in 2024 and is projected to reach around $1.95 billion by 2034.
• iovera system (cryoanalgesia device): Null

Pacira BioSciences (PCRX) is expected to drive future revenue growth over the next 2-3 years through several key initiatives and product expansions:

1. Accelerated EXPAREL Volume Growth and Expanded Market Access: Pacira anticipates continued growth from its flagship product, EXPAREL, driven by increased volume, broader commercial and government reimbursement access, and expanded patent protection extending through 2039. The NOPAIN Act is also cited as positively impacting the adoption and reimbursement of non-opioid alternatives, thereby enhancing EXPAREL's market presence.
2. Strategic Partnerships for ZILRETTA and International Expansion: The company's strategic collaboration with Johnson & Johnson MedTech is projected to significantly expand the market reach of ZILRETTA by tripling promotional efforts and extending its presence into new physician specialties. Additionally, a partnership with LG Chem is aimed at expanding EXPAREL and ZILRETTA coverage in select Asia-Pacific markets, with initial revenues expected in 2027.
3. Growing Adoption and Expanded Indications for iovera System: The iovera system is demonstrating promising outcomes in studies for chronic low back pain, showing better results than traditional radiofrequency ablation. Recent FDA clearance for a new SmartTip designed for deeper nerve access in lumbar applications further supports the potential for increased utilization and growth, particularly in spine-related pain management.
4. Advancement of Pipeline Products: Pacira is investing in and progressing its pipeline, including PCRX-201, a gene therapy for osteoarthritis, and PCRX-2002, a ropivacaine-based long-acting local analgesic. Key data readouts for these programs are anticipated, offering potential for future revenue streams beyond the current commercial portfolio.
5. Execution of the "5x30" Strategy: Pacira's overarching "5x30" strategy aims to significantly increase patient access to its products, targeting 3 million patients annually by 2030. This strategy emphasizes accelerating commercial portfolio growth, enhancing market penetration, and fostering continuous innovation across its product lines, thereby serving as a broad driver for revenue growth.

Share Repurchases

• Pacira BioSciences authorized a new share repurchase program of up to $300 million on April 17, 2025, which supersedes a previous authorization from May 7, 2024, and is set to expire on December 31, 2026.
• In 2025, the company completed $150 million in stock repurchases, reducing the shares outstanding to 41 million.
• From October 1, 2025, to December 31, 2025, Pacira repurchased 2,000,000 shares for $50 million, completing the repurchase of 5,932,106 shares for $150.05 million under the buyback announced on May 8, 2025.

Outbound Investments

• In February 2025, Pacira acquired the remaining 81% equity interest of GQ Bio Therapeutics GmbH for approximately $32 million, building on prior investments and partnerships for the development of a gene therapy platform.
• In November 2021, Pacira acquired Flexion Therapeutics for approximately $425 million, which strengthened its position in non-opioid pain management.
• Pacira BioSciences entered into an exclusive global licensing agreement with AmacaThera for US$230 million in November 2025.

Capital Expenditures

• Capital expenditures for Pacira BioSciences were $40 million in 2025, $25 million in 2024, $19 million in 2023, $15 million in 2022, and $10 million in 2021.
• The company has invested in its 200-liter facilities in Swindon and San Diego to enhance manufacturing efficiencies and ensure ample production capacity.